An2 Therapeutics, INC

AN2 Therapeutics reported Q2 2026 results, detailing progress in Phase 2 trials for polycythemia vera and Chagas disease, alongside pipeline expansion and increased R&D spending.

AN2 Therapeutics announced positive results from studies of its oral drug AN2-502998 for chronic Chagas disease, showing 100% parasite elimination in nonhuman primates and a favorable safety profile in human trials.

AN2 Therapeutics reported Q1 2026 results, highlighting progress in its oral epetraborole programs for polycythemia vera and M. abscessus lung disease, alongside a new ENPP1 candidate for solid tumors, while maintaining a projected cash runway into 2029.

AN2 Therapeutics has entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $80 million of its common stock.

AN2 Therapeutics, Inc. has repriced all outstanding stock options granted prior to March 19, 2026, to $3.91 per share to enhance retention and motivation.

AN2 Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting pipeline advancements and a private placement extending its cash runway into 2029.

AN2 Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in research and development, progress in clinical trials for epetraborole and AN2-502998, and a strong cash position.

AN2 Therapeutics, Inc. reported a net loss of $9.35 million for Q3 2025, narrowing losses year-over-year, while advancing its Chagas disease and oncology programs.

AN2 Therapeutics reported a significant reduction in net loss and cash burn for Q2 2025, driven by strategic restructuring and the discontinuation of its MAC lung disease program, while advancing its Chagas and oncology pipelines.

AN2 Therapeutics announces Q1 2025 financial results and reports that the truncated Phase 3 portion of the EBO-301 study for epetraborole did not meet its primary endpoint, leading to the discontinuation of its development for treatment-refractory MAC lung disease.

AN2 Therapeutics reports a net loss of $12.7 million for the third quarter of 2024 and announces a restructuring plan including a 50% workforce reduction.

AN2 Therapeutics reports its second quarter 2024 financial results and announces a restructuring plan including a workforce reduction after discontinuing a Phase 2/3 clinical trial for epetraborole.

AN2 Therapeutics focuses on its boron chemistry platform and pipeline programs for Chagas disease, NTM, melioidosis, and oncology after topline results from the Phase 2 part of the EBO-301 study.

AN2 Therapeutics has filed an amendment to its annual report to include previously omitted certification language regarding internal controls over financial reporting.

AN2 Therapeutics' annual 10-K filing details a pause in their Phase 3 clinical trial for epetraborole, along with updates on other pipeline programs and financial status.

Robin Shane Readnour, a Director of AN2 Therapeutics, Inc., sold 35,402 shares of common stock on August 17, 2026 for $6.01 per share.

Joseph S Zakrzewski, a Director of AN2 Therapeutics, Inc., reported a transaction in 405,880 shares of common stock on August 14, 2026.

AN2 Therapeutics Director Aziz Kabeer acquired 2,852 shares of common stock as compensation, increasing his indirect holdings.

Gilbert Lynn Marks, a Director at AN2 Therapeutics, Inc., acquired 2,789 shares of common stock on July 10, 2026, issued in lieu of cash compensation.

Patricia A. Martin, a Director at AN2 Therapeutics, Inc., acquired 766 shares of common stock on July 10, 2026, as part of her compensation.

AN2 Therapeutics COO and Chief Legal Officer Joshua M. Eizen reported a sale of 5,945 shares of common stock on July 8, 2026, to cover tax withholding obligations.

AN2 Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditors.

AN2 Therapeutics will hold its annual stockholders meeting on May 22, 2025, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.

AN2 Therapeutics will hold its 2025 Annual Meeting of Stockholders on May 22, 2025, to elect directors and ratify the appointment of its independent registered public accounting firm.

AN2 Therapeutics sets date for annual stockholders meeting on June 19, 2024, with key proposals including director elections and ratification of PricewaterhouseCoopers LLP as auditor.

AN2 Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 19, 2024, to vote on the election of directors, ratification of the independent accounting firm, and amendment of the certificate of incorporation.

BML Investment Partners, L.P. has filed an amended Schedule 13D, revealing a substantial reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 1.4% after a series of sales in May and June 2025.

BML Investment Partners, L.P. has filed an amended Schedule 13D, disclosing a reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 10.7% following recent sales.

BML Investment Partners, holding 19.1% of AN2 Therapeutics, has filed a Schedule 13D advocating for an orderly winddown, liquidation, and capital return to shareholders following the Phase 3 failure of the company's lead drug, EBO-301.

Almitas Capital LLC has reported a decreased ownership stake in AN2 Therapeutics, Inc., now holding 4.1% of the company's common stock.

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in AN2 Therapeutics, Inc., comprising common stock and pre-funded warrants.

Millennium Management LLC and affiliated entities have reported a collective beneficial ownership of 6.3% in AN2 Therapeutics, Inc. common stock.

Vivo Opportunity Fund Holdings and affiliates report an aggregate passive ownership of 8.8% in AN2 Therapeutics, Inc. common stock.

Almitas Capital LLC has reported a 5.2% beneficial ownership stake in AN2 Therapeutics, Inc., holding 1,428,323 shares of common stock and warrants.

Coastlands Capital LP and its affiliated entities have disclosed a passive beneficial ownership of 9.3% of AN2 Therapeutics, Inc.'s common stock.